Extra-musculoskeletal manifestations driving the therapeutic decision-making in patients with Spondyloarthritis: a 12-month follow-up prospective cohort study

Table 7 Therapeutic measures taken for patients with active IBD during 12-Month follow-up

Medications	Previous (N = 14)	Baseline (N = 14)	3 months (N = 8)	6 months (N = 4)	12 months (N = 4)	p
No medication, n (%)	4 (26.7%)	0	0	0	0
Oral Glucocorticoid, n (%)	3 (20%)	3 (20%)	2 (25%)	2 (50%)	1 (25%)	0.84
DMARDs, n (%)	3 (20%)	12 (60%)	5 (62.5%)	1 (25%)	3 (75%)	< 0.0001
AZA, n (%)	0	4 (26.7%)	1 (12.5%)	1 (25%)	2 (50%)	0.16
SSZ, n (%)	3 (20%)	8 (53.3%)	3 (37.5%)	0	1 (25%)	0.007
Mesalazine, n (%)	0	0	1 (12.5%)	0	0	0.41
Biologic agents, n (%)	6 (40%)	11 (73.3%)	5 (62.5%)	2 (50%)	3 (75%)	< 0.0001
Adalimumab, n (%)	2 (13.3%)	4 (26.7%)	3 (37.5%)	0	1 (25%)	0.08
Golimumab, n (%)	1 (6.7%)	1 (6.7%)	0	0	1 (25%)	0.63
Etanercept, n (%)	1 (6.7%)	0	0	0	0	0.41
Infliximab, n (%)	2 (13.3%)	2 (13.3%)	1 (12.5%)	1 (25%)	1 (25%)	0.60
Certolizumab, n (%)	0	0	1 (12.5%)	0	0	0.04
Ustekinumab, n (%)	0	0	0	1 (25%)	0	0.41

DMARDs: Disease-modifying anti-rheumatic drugs; AZA: azathioprine; SSZ: sulfasalazine

ISSN: 2523-3106